In this JCO Precision Oncology Article Insights episode, Jiasen He summarizes “Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma” by Dr. Miles C. Andrews, et al. published on June 07, 2024.
From An Overlooked Bump to Melanoma, One Survivor Shares His Journey. For CJ, a busy restaurant general manager getting ready for his 38th birthday, life was moving fast.
Oncolytic immunotherapeutic regimens, such as the oncolytic virus RP1 plus nivolumab (Opdivo), may offer a clinically meaningful option for patients with melanoma experiencing primary resistance to anti–PD-1 therapy
